What one share of Cabaletta Bio holds
We are a late clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases.
Cabaletta Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.55 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.31 |
| Cash and investments | $1.33 |
| Book value | $1.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$6.87 | — | — | — | — |
| 2019 | — | −$4.07 | $0.13 | −$3.06 | $0.00 | — |
| 2020 | — | −$1.44 | $0.03 | −$1.18 | — | $4.55 |
| 2021 | — | −$1.80 | $0.05 | −$1.37 | — | $4.08 |
| 2022 | — | −$1.81 | $0.08 | −$1.67 | — | $3.55 |
| 2023 | — | −$1.65 | $0.02 | −$1.32 | — | $4.94 |
| 2024 | — | −$2.34 | $0.04 | −$1.83 | — | $3.00 |
| 2025 | — | −$2.10 | $0.02 | −$1.66 | — | $1.12 |
Common questions about Cabaletta Bio
How much does one share of Cabaletta Bio earn?
Over the last 12 months, Cabaletta Bio lost $1.55 for each share.
Does Cabaletta Bio pay a dividend?
Cabaletta Bio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Cabaletta Bio’s book value per share?
Cabaletta Bio’s book value is $1.24 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Cabaletta Bio have?
Each share of Cabaletta Bio has $1.33 of cash and investments, as of June 30, 2026.
What is Cabaletta Bio’s free cash flow per share?
−$1.31 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Cabaletta Bio bought back shares?
Cabaletta Bio’s share count rose about 4400% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.